Esperion Therapeutics ESPR Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's total liabilities?
- Esperion Therapeutics (ESPR) reported total liabilities of $770.46M in Q1 2026.
- How has Esperion Therapeutics's total liabilities changed year-over-year?
- Esperion Therapeutics's total liabilities increased by 2.7% year-over-year, from $750.24M to $770.46M.
- What is the long-term trend for Esperion Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Esperion Therapeutics's total liabilities has grown at a 11.3% compound annual growth rate (CAGR), from $449.39M to $767.85M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.